Maze Therapeutics Inc [MAZE] stock prices are up 2.17% to $32.53 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MAZE shares have gain 13.74% over the last week, with a monthly amount glided 14.34%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, BTIG Research started tracking the stock with Buy rating on September 02, 2025, and set its price target to $30. On July 23, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $34 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $17 on July 08, 2025.
The stock price of Maze Therapeutics Inc [MAZE] has been fluctuating between $6.71 and $34.29 over the past year. Currently, Wall Street analysts expect the stock to reach $32.25 within the next 12 months. Maze Therapeutics Inc [NASDAQ: MAZE] shares were valued at $32.53 at the most recent close of the market. An investor can expect a potential drop of -0.86% based on the average MAZE price forecast.
Analyzing the MAZE fundamentals
The Maze Therapeutics Inc [NASDAQ:MAZE] reported sales of 0.00M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.18% with Operating Profit Margin at -50.33%, Pretax Profit Margin comes in at -48.54%, and Net Profit Margin reading is -48.32%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is 11.67 and Total Capital is -0.44. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 31.52 points at the first support level, and at 30.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 33.65, and for the 2nd resistance point, it is at 34.77.
Ratios To Look Out For
It’s worth pointing out that Maze Therapeutics Inc [NASDAQ:MAZE]’s Current Ratio is 17.70. As well, the Quick Ratio is 17.70, while the Cash Ratio is 13.29.
Transactions by insiders
Recent insider trading involved SCHELLER RICHARD H, Director, that happened on Sep 15 ’25 when 20744.0 shares were sold. Director, RICHARD SCHELLER completed a deal on Sep 15 ’25 to buy 20744.0 shares.
